Assessing the order of magnitude of outcomes in single-arm cohorts through systematic comparison with corresponding cohorts: An example from the AMOS study by Hamre, Harald J et al.
BioMed  Central
Page 1 of 13
(page number not for citation purposes)
BMC Medical Research 
Methodology
Open Access Research article
Assessing the order of magnitude of outcomes in single-arm 
cohorts through systematic comparison with corresponding 
cohorts: An example from the AMOS study
Harald J Hamre*1, Anja Glockmann1, Wilfried Tröger2, Gunver S Kienle1 and 
Helmut Kiene1
Address: 1Institute for Applied Epistemology and Medical Methodology, Freiburg, Germany and 2Director, Clinical Research Dr Tröger, Freiburg, 
Germany
Email: Harald J Hamre* - harald.hamre@ifaemm.de; Anja Glockmann - anja.glockmann@ifaemm.de; Wilfried Tröger - troeger@crdt.de; 
Gunver S Kienle - gunver.kienle@ifaemm.de; Helmut Kiene - helmut.kiene@ifaemm.de
* Corresponding author    
Abstract
Background: When a therapy has been evaluated in the first clinical study, the outcome is often compared
descriptively to outcomes in corresponding cohorts receiving other treatments. Such comparisons are often
limited to selected studies, and often mix different outcomes and follow-up periods. Here we give an example of
a systematic comparison to all cohorts with identical outcomes and follow-up periods.
Methods: The therapy to be compared (anthroposophic medicine, a complementary therapy system) had been
evaluated in one single-arm cohort study: the Anthroposophic Medicine Outcomes Study (AMOS). The five
largest AMOS diagnosis groups (A-cohorts: asthma, depression, low back pain, migraine, neck pain) were
compared to all retrievable corresponding cohorts (C-cohorts) receiving other therapies with identical outcomes
(SF-36 scales or summary measures) and identical follow-up periods (3, 6 or 12 months). Between-group
differences (pre-post difference in an A-cohort minus pre-post difference in the respective C-cohort) were
divided with the standard deviation (SD) of the baseline score of the A-cohort.
Results: A-cohorts (5 cohorts with 392 patients) were similar to C-cohorts (84 cohorts with 16,167 patients)
regarding age, disease duration, baseline affection and follow-up rates. A-cohorts had ≥ 0.50 SD larger
improvements than C-cohorts in 13.5% (70/517) of comparisons; improvements of the same order of magnitude
(small or minimal differences: -0.49 to 0.49 SD) were found in 80.1% of comparisons; and C-cohorts had ≥ 0.50
SD larger improvements than A-cohorts in 6.4% of comparisons. Analyses stratified by diagnosis had similar
results. Sensitivity analyses, restricting the comparisons to C-cohorts with similar study design (observational
studies), setting (primary care) or interventions (drugs, physical therapies, mixed), or restricting comparisons to
SF-36 scales with small baseline differences between A- and C-cohorts (-0.49 to 0.49 SD) also had similar results.
Conclusion: In this descriptive analysis, anthroposophic therapy was associated with SF-36 improvements largely
of the same order of magnitude as improvements following other treatments. Although these non-concurrent
comparisons cannot assess comparative effectiveness, they suggest that improvements in health status following
anthroposophic therapy can be clinically meaningful. The analysis also demonstrates the value of a systematic
approach when comparing a therapy cohort to corresponding therapy cohorts.
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Background
In the early phase of the clinical evaluation of a therapy,
when first study results are published, it can be desirable
to assess outcomes of this reference therapy relative to
outcomes of other treatments for the disease in question.
At this stage, a systematic review of controlled studies of
the reference therapy vs. other treatments will give limited
information, because few such studies will be available.
An alternative is to compare the reference cohort (or
cohorts) to all corresponding cohorts, i. e. to single-arm
cohorts and therapy arms in controlled studies, receiving
other treatments. Although such 'all corresponding
cohorts comparisons' cannot assess comparative effective-
ness, they nevertheless yield information about the order
of magnitude of treatment outcomes. For therapies which
have been evaluated exclusively in single-arm studies (e. g.
many drugs [1-4], surgery [5-8], other procedures [9,10]),
'corresponding cohort comparisons' remain the only pos-
sibility.
Brief comparisons with corresponding cohorts are often
presented in discussion sections of papers (e. g. [11,12]),
and are often unsystematic (limited to selected studies)
and imprecise (mixing different outcomes and follow-up
periods). Here we give an example of a systematic com-
parative review, restricted to cohorts with identical out-
come measures and comparable follow-up periods. Since
the cohorts compared are derived from different studies,
the comparisons are necessarily explorative and the anal-
yses descriptive: results are not pooled, but are ordered in
increasing magnitude.
Methods
Reason for the review
The reference therapy (anthroposophic medicine, a physi-
cian-provided complementary therapy system including
counselling, medication, art and movement exercises, and
massage) had been evaluated in a large single-arm cohort
study: the Anthroposophic Medicine Outcomes Study
(AMOS) [13]. AMOS was conducted in 1998–2005 in
Germany. Outpatients with chronic disorders were
enrolled before starting anthroposophic therapy and fol-
lowed up for four years [14-17].
For the five largest AMOS diagnosis groups in adult
patients (asthma, depression [18], low back pain [19],
migraine, and neck pain), AMOS is so far the only outpa-
tient study of anthroposophic therapy for the respective
diagnoses [20]. In all five groups, changes in health status
had been evaluated with the SF-36 Health Survey, which
is widely used [21], enabling comparisons to other
cohorts. We conducted a systematic review, comparing
these five cohorts (A-cohorts, 392 patients from 90 medi-
cal practices, enrolled up to 31 December 2005) to all
retrievable patient cohorts (C-cohorts) with correspond-
ing diagnoses, outcome measure (SF-36), and follow-up
periods.
Objective
The objective of this systematic review was to assess the
comparative order of magnitude of pre-post changes in
health status in adult patients receiving anthroposophic
therapy for one of five chronic diseases.
Eligible comparison studies
For comparison to A-cohorts, we considered prospective
studies from any setting in any country with any therapeu-
tic intervention including treatment-as-usual, and with a
cohort of at least 20 evaluable patients, published in Dan-
ish, English, German, French, Italian, Norwegian, Rus-
sian, Spanish or Swedish.
Studies were eligible if at least 80% of participants of the
study or of a defined subgroup had one of the following
five diagnoses occurring in at least 20 adult AMOS
patients: asthma, depression, low back pain, migraine,
and neck pain. No requirements of diagnostic criteria
were made. Low back pain cohorts with more than 25%
patients with congenital spinal malformations, spinal
infectious or malignant disease, ankylosing spondylitis,
Behcet's Syndrome, Reiter's Syndrome, osteoporosis with
vertebral fracture, spinal stenosis, spondylolysis, spondy-
lolisthesis, fibromyalgia, traumatic vertebral fracture or
previous spinal operations were excluded from the analy-
sis (these diagnoses were excluded from the correspond-
ing A-cohort). Studies with all persons aged ≥ 60 years
were also excluded (only 12% of A-patients were aged ≥
60 years).
Studies were required to have at least one of the following
ten outcomes from the SF-36 Health Survey, four-week
version: eight SF-36 scales (Physical Function, Role Phys-
ical, Role Emotional, Social Functioning, Mental Health,
Bodily Pain, Vitality, General Health), SF-36 Physical
Component Summary Measure or SF-36 Mental Compo-
nent Summary Measure. The outcome was included if the
arithmetic mean was presented with a number or could be
estimated from a figure (a) before commencement of any
study intervention, and (b) after three, six, or 12 months
(± 20%).
Literature search
We searched Ovid MEDLINE, Ovid MEDLINE In-Process
& Other Non-Indexed Citations, Journals@Ovid full text,
BIOSIS Previews, Cochrane Database of Systematic
Review, American College of Physicians Journal Club,
Database of Abstracts of Reviews of Effects, Cochrane
Central Register of Controlled Trials, Psychlit, the online
SF-36 database [22], literature references of retrieved arti-BMC Medical Research Methodology 2008, 8:11 http://www.biomedcentral.com/1471-2288/8/11
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cles and our own literature archive. Articles published up
to December 2005 were considered.
The general search strategy was: "SF-36 keyword" in title,
abstract or keyword AND "disease keyword" in title. SF-36
keywords were "SF-36" OR "Short-Form" OR "Medical
Outcomes" OR "Quality of Life" OR "Disability" OR
"Outcome Assessment (Health Care)". Disease keywords
were "Asthma" OR "Depress*" OR "Dysthymic disorder"
OR "Low back pain" OR "Spinal diseas*" OR "Migraine"
OR "Neck Pain" OR ["Spinal Diseas*" AND "Neck"].
Articles were read and assessed for provisional inclusion
by one reviewer. All provisionally included articles were
re-assessed for fulfilment of eligibility criteria by a second
reviewer. Disagreements about fulfilment of eligibility cri-
teria were resolved by discussion. Data of included articles
were extracted and entered into Microsoft Excel data files
by one person; all entered data were subject to source doc-
ument verification by another person.
Analysis
Units of analysis were individual SF-36 outcomes of the
smallest statistically independent cohorts. Data from
cohorts which were not statistically independent (e. g.
patients randomised to drug therapy with or without
information booklet, outcomes not differing between the
two treatment groups) were pooled prior to analysis.
For each C-cohort, the following study characteristics were
extracted and tabulated: diagnosis, publication year, eval-
uable SF-36 outcomes, sample size at baseline, last evalu-
able follow-up, follow-up rates, design, setting, country,
age, gender, disease duration, and study treatment.
The statistical analysis (SPSS 14.0) was descriptive. For
each evaluable SF-36 outcome of a C-cohort, the pre-post
difference (mean score at last evaluable follow-up minus
mean baseline score) was subtracted from the correspond-
ing difference of the respective A-cohort, yielding a mean
outcome difference ((MeanA-FU - MeanA-0) - (MeanC-FU -
MeanC-0)). For each of the ten SF-36 outcomes, mean out-
come differences were analysed with summary statistics of
distribution of the differences. In order to aggregate all
differences of all outcomes, the differences were also
expressed as between-group effect sizes through division
by the standard deviation (SD) of the baseline score of the
A-cohort ((MeanA-FU - MeanA-0) - (MeanC-FU - MeanC-0)/
SDA-0). The baseline SD of the A-cohort was used instead
of the SD of the C-cohort or a pooled SD from A- and C-
cohorts because the SD was not available for many C-
cohorts. To avoid redundancy when aggregating differ-
ences across SF-36 outcomes, comparisons of SF-36 Phys-
ical and Mental Component Summary Measures were not
included if, for the C-cohort in question, all the eight SF-
36 scales were evaluable for comparison. Effect sizes and
baseline differences were classified as large (≥ 0.80),
medium (0.50–0.79), small (0.20–0.49) and minimal
(0.00–0.19) [23,24]. An improvement of the same order
of magnitude was defined as a minimal-to-small effect
size (range -0.49 to 0.49). Due to the descriptive nature of
this analysis, no hypothesis testing was performed.
Analyses were performed for all comparisons and strati-
fied by SF-36 outcomes, by diagnoses, and both. In addi-
tion, four sensitivity analyses (SA1-4) were performed in
order to study effects of reducing the heterogeneity of the
comparisons. In each SA, between-group effect sizes were
reanalysed, restricting the number of comparisons accord-
ing to study design, setting, intervention or baseline sta-
tus: In SA1, study designs of C-cohorts were restricted to
observational studies (non-randomised comparative
studies and single-arm cohorts), i.e. excluding ran-
domised trials, because the randomisation prerequisite
might lead to a selection of patients with different charac-
teristics, compared to observational studies such as
AMOS. In SA2, settings of C-cohorts were restricted to pri-
mary care or health maintenance organizations, because
most A-patients were recruited in primary care. In SA3,
treatments of C-cohorts were restricted to drugs, physio-
therapy or other physical therapies or mixed treatments,
because these interventions were deemed to be most sim-
ilar to the AMOS treatment modalities. In SA4, compari-
sons were restricted to SF-36 scales with small baseline
differences (maximum 0.49 SD) between the respective A-
and C-cohorts, because scales with large baseline differ-
ences may have differing room for improvement follow-
ing therapy, for regression to the mean etc.
Results
Excluded publications
A total of 530 publications were excluded from this review
for the following reasons: diagnosis not fulfilling eligibil-
ity criteria (n = 192 publications), no follow-up data (n =
129), no SF-36 data (n = 55), multiple publications (n =
43), SF-36 data presented without means (n = 31), cohort
with all patients ≥ 60 years (n = 27), duration of follow-
up differing > 20% from three, six, and 12 months, respec-
tively (n = 20), no baseline SF-36 data (n = 12), cohort
with < 20 patients (n = 8), SF-36 acute form only (n = 3),
modified SF-36 (n = 3), language not fulfilling eligibility
criteria (n = 2), no trial (n = 1), other (n = 4). A table of
excluded publications with reasons for exclusion is pro-
vided in Additional file 1.
Description of AMOS cohorts and corresponding cohorts
All diagnoses analysed together
The five A-cohorts with a total of 392 patients were com-
pared to 84 C-cohorts with 16,167 patients. These 84 C-
cohorts were presented in 63 publications (Table 1, forBMC Medical Research Methodology 2008, 8:11 http://www.biomedcentral.com/1471-2288/8/11
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details see also Additional file 2). Diagnoses are described
below and in Additional file 3. Seven of the 84 C-cohorts
were published in the period 1994–1996, 15 in 1997–
1999, 23 in 2000–2002 and 39 were published in 2003–
2005. Evaluable outcomes of C-cohorts were: all eight SF-
36 scales (n = 40 of 84 C-cohorts), SF-36 Physical or Men-
tal Component Summary Measures or both (n = 11), all
eight SF-36 scales plus SF-36 Physical or Mental Compo-
nent Summary Measures or both (n = 20), less than all
eight SF-36 scales (n = 13).
Median sample size per cohort was 56 patients (interquar-
tile range (IQR) 41–127 patients) for A-cohorts and 137
patients (IQR 65–244) for C-cohorts. The last evaluable
follow-up ensued after three months in 23 of 84 C-
cohorts, after six months in 32 C-cohorts and after 12
months in 29 C-cohorts. Three-month-follow-up rates
were 87.5% and 83.0% in A- and C-cohorts, respectively;
six-month rates were 82.1% and 79.1%; and 12-month
rates were 78.8% and 72.2%.
Study designs of C-cohorts were randomised controlled
trials (n = 40 of 84 C-cohorts), non-randomised compar-
ative studies (n = 9) and single-arm cohort studies (n =
35). Study settings of A-patients were primary care prac-
tice (85.5%, 337 of 389 evaluable A-patients), referral
practice (10.5%), and outpatient clinic (2.8%). Study set-
tings of C-cohorts were primary care or health mainte-
nance organization (n = 27 C-cohorts, 33.6% (5427/
16,167) of C-patients), non-academic hospital or outpa-
tient clinic (n = 19 C-cohorts, 25.2% of C-patients), aca-
demic hospital or outpatient clinic (n = 27, 22.0%) and
other or not specified (n = 11, 18.1%).
The 84 C-cohorts came from the USA (n = 37), Germany
(n = 13), United Kingdom (n = 11), Canada (n = 4), Aus-
tralia (n = 3), Japan (n = 3), Italy (n = 2), Spain (n = 2),
from eight other countries (each C-cohort: n = 1) and
from more than one country (n = 1).
Mean age, weighted for sample size, was 44.4 years (SD
11.6) in A-cohorts and 44.4 years in C-cohorts (evaluable
in 76 of 84 C-cohorts). The percentage of women was
83.2% (326/392) in A-cohorts and 59.6% (8,897/14,927)
in C-cohorts (evaluable in 77 C-cohorts). Mean disease
duration, weighted for sample size, was 10.5 years (SD
12.8) in A-cohorts and 12.8 years in C-cohorts (evaluable
for 14 of 84 C-cohorts).
Main anthroposophic treatment modalities in A-patients
were: eurythmy therapy (45.4%, 178 of 392 A-patients),
art therapy (26.5%), rhythmical massage therapy
(11.5%), and physician-provided anthroposophic ther-
apy (16.6%). Study treatments in C-cohorts were: drugs
(n = 32 of 84 C-cohorts, 47.3%, 7,655 of 16,167 C-
patients), treatment-as-usual (n = 17 C-cohorts, 14.9% of
C-patients), surgery (n = 8, 9.0%), physiotherapy (n = 4,
10.1%), other physical therapy (n = 5, 1.4%), educational
intervention (n = 7, 5.9%), and mixed or other therapy (n
= 11, 11.4%).
Analyses stratified by diagnoses
Data on gender, age, study design, setting, disease dura-
tion at baseline, study treatments, last follow-up and fol-
low-up rates, stratified by diagnosis, are presented in
Additional file 3. The diagnosis neck pain had only two C-
cohorts; therefore, the following description refers to the
remaining diagnoses – asthma, depression, low back pain
and migraine – with a range of 12–30 C-cohorts per diag-
nosis. In all four diagnoses, the percentage of women was
higher in A-cohorts than in C-cohorts; absolute percent
differences ranged from 9% (asthma: 70% and 61%
women in A- and C-cohorts, respectively) to 44% (low
back pain: 86% and 42% women). Age was similar in A-
and C-cohorts. In C-cohorts the proportion of ran-
domised trials was higher in depression (84%, 16 of 19 C-
cohorts) than in other diagnoses (range 19%–43%). In A-
patients the proportion recruited in primary care was
lower in asthma (48%, 27 of 56 patients) than in other
diagnoses (88%–97%). Correspondingly, the proportion
Table 1: Overview of cohorts, patients and diagnoses
Diagnosis AMOS cohorts Corresponding cohorts
Cohorts Patients Patients per cohort Publications Cohorts Patients Patients per cohort
N N Percent Mean N N N Percent Mean
Asthma 1 56 14.3% 56 11 12 2,030 12.6% 169
Depression 1 174 44.4% 174 13 19 4,440 27.5% 234
Low back pain 1 80 20.4% 80 24 30 4,701 29.1% 157
Migraine 1 42 10.7% 42 13 21 4,240 26.2% 202
Neck pain 1 40 10.2% 40 2 2 756 4.7% 378
Total 5 392 100.0% 78 63 84 16,167 100.0% 192BMC Medical Research Methodology 2008, 8:11 http://www.biomedcentral.com/1471-2288/8/11
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of C-cohorts recruited in primary care/health mainte-
nance organization settings was lowest for asthma (8%, 1
of 12 C-cohorts) and highest in depression (74%, 14 of 19
C-cohorts). In asthma, disease duration was similar in A-
and C-cohorts (median 14.5 years and 14.5 years, respec-
tively; n = 6 evaluable C-cohorts), the other diagnoses had
only 1–3 cohorts with evaluable data on disease duration.
Most frequent study treatments in C-cohorts were drugs
(migraine, asthma, depression: 71%, 58% and 42% of C-
cohorts, respectively) and treatment-as-usual (low back
pain, 30% of C-cohorts). Follow-up-rates of A- and C-
cohorts differed little across diagnoses.
Comparisons between AMOS cohorts and corresponding 
cohorts
For separate analysis of individual SF-36 scales, a total of
552 comparisons between A-cohorts and C-cohorts were
possible (Tables 2, 3, 4 Fig. 1). For aggregated analysis of
all SF-36 scales, comparisons of SF-36 Physical and Men-
tal Component Summary Measures were excluded for
cohorts with all eight SF-36 scales evaluable (35 excluded
comparisons), resulting in 517 comparisons.
Main analysis: all diagnoses and SF-36 scales analysed together (517 
comparisons)
At baseline (Table 5), A-cohorts were slightly more
severely affected than C-cohorts (median difference 0.22
SD, IQR -0.13 to +0.53); baseline differences between A-
and C-cohorts were minimal or small (-0.49 SD to 0.49
SD) in 65.6% (339/517) of the comparisons; medium-to-
large (≥ 0.50 SD) with A-cohorts more severely affected
than C-cohorts in 26.5% of the comparisons; and
medium-to-large with C-cohorts more severely affected in
7.9% of the comparisons.
At follow-up (Table 6, Fig. 2, All diagnoses), outcome
comparisons showed effect sizes (pre-post improvements
of A-cohorts minus pre-post improvements of C-cohorts
divided by standard deviation of baseline score of A-
cohorts) with a median of 0.11 (IQR -0.11 to 0.35).
• Effect sizes were positive, i. e. showing larger (≥ 0.20)
improvements of A-cohorts than of C-cohorts in 41.0%
(212/517) of the comparisons. These positive effect sizes
were large (≥ 0.80) in 3.3% of the comparisons, medium
(0.50–0.79) in 10.3% and small (0.20–0.49) in 27.5% of
the comparisons.
• Effect sizes showed minimal differences (-0.19 to 0.19)
between A- and C-cohorts in 41.4% of the comparisons.
• Effect sizes were negative, i. e. showing larger improve-
ments of C-cohorts than of A-cohorts in 17.6% of the
comparisons. These negative effect sizes were large (≥
0.80) in 2.5% of the comparisons, medium (0.50–0.79)
in 3.9% and small (0.20–0.49) in 11.2% of the compari-
sons.
The proportion of comparisons showing improvements
in A- and C-cohorts of the same order of magnitude (min-
imal-to-small effect sizes, range -0.49 to 0.49) was 80.1%
(414 of 517 comparisons).
Analyses stratified by SF-36 scales (552 comparisons)
Baseline scores of individual SF-36 scales in A- and C-
cohorts are presented in Table 2, baseline between-group
differences in standard deviations in Table 3. At baseline,
A-cohorts were more severely affected than C-cohorts for
8 SF-36 scales, with median differences ranging from 0.05
SD (Role Physical, Bodily Pain) to 0.54 (General Health),
while C-cohorts were more severely affected for 2 scales,
with median differences of 0.14 (Physical Functioning)
and 0.40 (Physical Component Summary). The propor-
tion of baseline comparisons with minimal-to-small dif-
ferences (-0.49 SD to 0.49 SD) ranged from 44% (General
Health) to 81% (Role Physical, Role Emotional).
Outcome comparisons of individual SF-36 scales are pre-
sented in Table 2 (score differences) and in Table 4 and
Fig. 1 (effect sizes). Median effect sizes ranged from -0.05
(Role Emotional) to 0.27 (Physical Component Sum-
mary), while the proportion of outcome comparisons
with minimal-to-small differences (-0.49 to +0.49) ranged
from 67% (Bodily Pain) to 93% (Role Emotional).
Analyses stratified by diagnosis (517 comparisons)
The diagnosis neck pain had only 10 comparisons; there-
fore the following description refers to the remaining
diagnoses – asthma, depression, low back pain and
migraine – with a range of 77–202 comparisons per diag-
nosis.
At baseline (Table 5), A-cohorts were more severely
affected than C-cohorts in all four diagnoses: the median
baseline difference in standard deviations (0.22 for all
cohorts) ranged from 0.02 (asthma) to 0.42 (migraine),
while the proportion of baseline comparisons with small
baseline differences (-0.49 to +0.49 SD; 66% for all com-
parisons) ranged from 57% (migraine) to 86% (asthma).
Outcome comparisons in effect sizes (Table 6) showed
very little variation: the median effect size (0.11 for all
comparisons) ranged from 0.05 (asthma) to 0.17 (depres-
sion), while the proportion of comparisons with mini-
mal-to-small differences (-0.49 to +0.49; 80% for all
comparisons) ranged from 77% (depression and low back
pain) to 85% (migraine).
Analyses stratified by SF-36 scales and diagnoses (552 comparisons)
These analyses are presented in Additional file 4.BMC Medical Research Methodology 2008, 8:11 http://www.biomedcentral.com/1471-2288/8/11
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Outcome comparisons stratified by individual SF-36 scales Figure 1
Outcome comparisons stratified by individual SF-36 scales. Differences between pre-post improvements of AMOS 
cohorts and improvements of corresponding cohorts for the eight SF-36 scales (0–100) and the SF-36 Physical and Mental 
Component Summary measures, expressed in effect sizes and ordered in increasing magnitude for each scale (altogether n = 
552 comparisons). Positive differences indicate larger pre-post improvement in AMOS cohort than in corresponding cohort.
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Sensitivity analyses
Four sensitivity analyses were performed (Table 7, see
Methods for details). SA1, SA2 and SA4 had very small
effects on the outcome differences: in each analysis the
median effect size was reduced from 0.11 to 0.08, while
the proportion comparisons with minimal-to-small dif-
ferences (-0.49 to +0.49 SD; 80% for all comparisons)
ranged from 83% to 88%. In SA3, study settings of C-
cohorts were restricted to primary care or health mainte-
nance organizations, whereby the median effect size was
increased from 0.11 to 0.24, while the proportion of com-
parisons with minimal-to-small differences was increased
to 88%. The combination of SA1 + SA2 + SA3 + SA4
yielded only 5 evaluable cohorts with 16 comparisons,
while results differed little from the main analysis
(median effect size 0.07; minimal-to-small differences in
94% of comparisons).
Discussion
We have presented a systematic comparative review of SF-
36 outcomes in five chronic conditions (asthma, depres-
sion, low back pain, migraine, neck pain). The review was
prompted by the availability of results from the first study
of a given therapy (the AMOS study of anthroposophic
medicine in outpatients with various chronic diseases
[13]). The objective was to assess the order of magnitude
of AMOS outcomes, relative to outcomes of other thera-
pies. For this purpose we compared AMOS diagnostic sub-
groups (A-cohorts) to all retrievable patient cohorts (C-
cohorts) with corresponding diagnoses, outcome meas-
ures and follow-up periods. More than 500 comparisons
of ten different SF-36 scales showed improvements largely
of the same order of magnitude in corresponding A- and
C-cohorts (minimal-to-small differences in 80% of the
comparisons); with medium-to-large differences favour-
ing A- and C-groups in 14% and 7% of the comparisons,
respectively.
This systematic review has five characteristic features: 1)
we compared one reference therapy to all other treatments
for the respective indications; 2) each comparison was of
corresponding cohorts from different studies; 3) compar-
isons were restricted to cohorts with identical outcome
measure and comparable follow-up periods; 4) analyses
were descriptive, with results ordered in increasing magni-
tude instead of being pooled; and 5) different outcomes
were converted to a common metric, allowing for data
synthesis into one variable. We are not aware of other sys-
tematic reviews combining these five features.
This type of review can be regarded as a systematic exten-
sion and upgrading of the common 'discussion-reviews'
in publications presenting new therapies, where results of
the first therapy study are compared descriptively to
results of other treatments for the given indication. In
contrast to such narrative reviews, the present review has
the strengths of systematic, criteria-based literature selec-
tion and analysis.
For complementary and other complex therapy systems in
widespread use regardless of whether evidence from ran-
domised trials exists, it has been argued that the conven-
tional drug research strategy – starting with studies of
biological mechanisms and moving through Phase I, II
and III clinical trials – should be replaced by a more
appropriate strategy, moving from descriptive studies
('Phase 1') towards comparative studies of the whole sys-
tem and its parts, and ending with studies of biological
mechanisms ('Phase 5') [25]. In the context of this
reversed strategy, the present review would represent an
intermediate step between Phases 1–2 (studies of para-
Table 2: Baseline scores and outcome comparisons, stratified by SF-36 scales.
SF-36 scale Baseline Follow-up
AMOS patients (N = 392 patients in 5 cohorts) Corresponding cohorts (N = 552 cohorts) Outcome differences (N = 552 comparisons)
Mean * SD * Median * N Mean ** SD ** Median ** Mean *** SD *** 25-per *** Median *** 75-per ***
Physical Function 72.8 23.8 80.0 62 65.1 19.2 68.6 0.6 9.4 -2.0 2.0 4.4
Role Physical 37.4 38.5 25.0 59 40.0 18.3 43.4 4.1 14.1 -6.3 5.0 12.4
Role Emotional 42.4 41.5 33.3 59 59.2 16.6 62.2 -0.2 11.3 -7.5 -2.0 7.7
Social Functioning 54.8 25.1 50.0 66 61.0 12.9 60.7 2.6 9.2 -2.8 2.0 8.8
Mental Health 49.3 20.9 48.0 62 61.9 10.9 64.0 2.0 6.7 -0.9 2.2 6.4
Bodily Pain 48.8 28.1 41.0 64 45.8 15.5 44.8 2.7 10.0 -1.7 2.8 9.2
Vitality 34.3 18.0 35.0 60 45.6 9.6 47.4 3.4 6.9 -1.0 3.9 8.7
General Health 48.3 19.9 47.0 63 60.3 10.2 60.3 2.9 5.4 -1.3 4.0 6.9
Physical Component 41.7 10.2 41.3 27 37.3 7.6 37.7 1.5 3.9 -0.3 2.4 3.9
Mental Component 35.6 12.7 34.0 30 40.4 7.7 42.4 0.3 5.0 -3.6 -0.5 3.7
*of patients. **of cohorts. ***of differences. N: Number of cohorts. 25-per: 25-percentile. 75-per: 75-percentile. Each outcome difference refers 
to one SF-36 scale at the last evaluable follow-up of the corresponding cohort: Mean difference from baseline in AMOS cohort minus mean 
difference from baseline in corresponding cohort. A positive difference indicates that AMOS cohorts show larger improvements than 
corresponding cohorts.BMC Medical Research Methodology 2008, 8:11 http://www.biomedcentral.com/1471-2288/8/11
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digms, utilization, perceived benefit and safety) and
Phase 3 (comparative effectiveness studies).
Notably, the present review is limited to comparative
order of magnitude. For our review, data from one single-
arm study were available. Accordingly, each single com-
parison was of two cohorts derived from different studies.
The only predefined criteria were comparable diagnosis
and follow-up period, and identical outcome measure. A-
and C-cohorts were found to be similar regarding age, dis-
ease duration, baseline affection and follow-up rates, and
different regarding sample size and gender. Sensitivity
analyses, restricting the number of comparisons to
increase comparability of study design, settings, therapy,
and baseline scores, had only small effects on the results.
Notably, representative data on disease duration in C-
cohorts was only available for one out of five diagnoses
(asthma). Furthermore, only 15% of C-cohorts were from
the same country as the A-cohorts (Germany). Other
study characteristics of interest, including screening data,
comorbidity and the use of adjunctive therapies, were
only sparingly and heterogeneously documented in C-
cohorts and hence were not evaluable. Because of the
residual heterogeneity in these non-concurrent compari-
sons, the assessment could not be aimed at statistical pre-
cision. The analyses were purely descriptive, without
attempting to pool data or to adjust for within-group dif-
ferences (except simple adjustment for differences in base-
line scores).
Our search strategy was limited to ten online databases,
thus some eligible studies may have been missed. Sample
sizes were less than 50 patients for A-cohorts with
migraine and neck pain. Furthermore, only two cohorts
with neck pain were available for comparison. Otherwise,
a range of patient settings (primary care, clinic, academic
hospital) and treatments (as-usual, drugs, physical thera-
pies, educational intervention, surgery) were represented
in the primary analyses of C-cohorts. Finally, the present
review was restricted to a generic health status instrument
(SF-36). Disease-specific comparisons might be more sen-
sitive to relevant differences undetected by this review. On
the other hand, anthroposophic therapy aims to improve
a broad range of symptoms and functional limitations
Table 3: Baseline differences in standard deviations, stratified by SF-36 scales. Each comparison refers to one SF-36 scale at baseline: 
Mean score in AMOS cohort minus mean score in corresponding cohort, divided by standard deviation of score in AMOS cohort. A 
negative difference indicates that AMOS cohorts have worse health status than corresponding cohorts at baseline.
SF-36 scale Median Interquartile range Ranges: Number (percentage) of comparisons N (total)
≤ -0.8 -0.79 to -0.5 -0.49 to -0.2 -0.19 to 0.19 0.2 to 0.49 0.5 to 0.79 ≥ 0.8
Physical Functioning 0.14 -0.20 to 0.72 0 (0) 0 (0) 16 (26) 19 (31) 9 (15) 7 (11) 11 (18) 62 (100)
Role Physical -0.05 -0.40 to 0.30 3 (5) 6 (10) 15 (25) 15 (25) 18 (31) 2 (3) 0 (0) 59 (100)
Role Emotional -0.14 -0.39 to 0.07 1 (2) 9 (15) 15 (25) 26 (44) 7 (12) 1 (2) 0 (0) 59 (100)
Social Functioning -0.24 -0.56 to 0.18 7 (11) 14 (21) 15 (23) 14 (21) 10 (15) 5 (8) 1 (2) 66 (100)
Mental Health -0.41 -0.59 to -0.19 7 (11) 17 (27) 22 (35) 13 (21) 2 (3) 1 (2) 0 (0) 62 (100)
Bodily Pain -0.05 -0.41 to 0.13 7 (11) 7 (11) 10 (16) 29 (45) 6 (9) 4 (6) 1 (2) 64 (100)
Vitality -0.41 -0.63 to -0.22 10 (17) 12 (20) 24 (40) 13 (22) 1 (2) 0 (0) 0 (0) 60 (100)
General Health -0.54 -0.84 to -0.10 19 (30) 14 (22) 14 (22) 9 (14) 5 (8) 2 (3) 0 (0) 63 (100)
Physical Component Summary 0.40 -0.12 to 0.84 0 (0) 3 (11) 2 (7) 5 (19) 6 (22) 4 (15) 7 (26) 27 (100)
Mental Component Summary -0.17 -0.55 to 0.06 2 (7) 8 (27) 4 (13) 13 (43) 3 (10) 0 (0) 0 (0) 30 (100)
Table 4: Outcome comparisons in effect sizes, stratified by SF-36 scales. Each comparison refers to one SF-36 scale at the last 
evaluable follow-up of the corresponding cohort: Mean difference from baseline in AMOS cohort minus mean difference from baseline 
in corresponding cohort, divided by standard deviation of baseline score of AMOS cohort. A positive difference indicates that AMOS 
cohorts show larger improvements than corresponding cohorts.
SF-36 scale Median Interquartile range Ranges: Number (percentage) of comparisons N (total)
≤ -0.8 -0.79 to -0.5 -0.49 to -0.2 -0.19 to 0.19 0.2 to 0.49 0.5 to 0.79 ≥ 0.8
Physical Functioning 0.09 -0.09 to 0.20 4 (6) 2 (3) 6 (10) 35 (56) 12 (19) 1 (2) 2 (3) 62 (100)
Role Physical 0.13 -0.16 to 0.35 0 (0) 1 (2) 10 (17) 24 (41) 17 (29) 6 (10) 1 (2) 59 (100)
Role Emotional -0.05 -0.18 to 0.21 1 (2) 1 (2) 10 (17) 32 (54) 13 (22) 2 (3) 0 (0) 59 (100)
Social Functioning 0.09 -0.12 to 0.37 0 (0) 6 (9) 7 (11) 24 (36) 18 (27) 6 (9) 5 (8) 66 (100)
Mental Health 0.12 -0.05 to 0.33 2 (3) 2 (3) 4 (6) 28 (45) 18 (29) 6 (10) 2 (3) 62 (100)
Bodily Pain 0.12 -0.06 to 0.44 4 (6) 3 (5) 5 (8) 25 (39) 13 (20) 11 (17) 3 (5) 64 (100)
Vitality 0.23 -0.06 to 0.52 1 (2) 3 (5) 7 (12) 16 (27) 18 (30) 11 (18) 4 (7) 60 (100)
General Health 0.20 -0.06 to 0.36 0 (0) 1 (2) 6 (10) 24 (38) 24 (38) 8 (13) 0 (0) 63 (100)
Physical Component Summary 0.27 -0.03 to 0.36 1 (4) 1 (4) 4 (15) 7 (26) 10 (37) 4 (15) 0 (0) 27 (100)
Mental Component Summary -0.03 -0.31 to 0.34 2 (7) 2 (7) 6 (20) 10 (33) 6 (20) 3 (10) 1 (3) 30 (100)BMC Medical Research Methodology 2008, 8:11 http://www.biomedcentral.com/1471-2288/8/11
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rather than only disease-specific symptoms [26], and
broad instruments like the SF-36 may therefore be partic-
ularly appropriate [19].
Within the limits of non-concurrent comparisons, this
review suggests that anthroposophic therapy for chronic
asthma, back or neck pain, depression and migraine can
be associated with improvements of SF-36 scales of largely
the same order of magnitude as improvements following
other treatments. This implication may sound trivial, but
is not. If our analyses had shown mostly small improve-
ments compared to other treatments, one might have con-
cluded that further studies of SF-36 as outcome of
anthroposophic therapy are not worthwhile. Had our
analysis shown large differences favouring anthropo-
sophic treatment, results would have appeared more
impressive. Had our results been very heterogeneous
(showing mostly large differences in both directions) it
would have been necessary to compare C-cohorts with
large positive and negative differences, respectively, to see
if these two sets of cohorts differ systematically in other
respects. The present results suggest that anthroposophic
therapy can be associated with clinically meaningful
improvements of health status.
The analysis also demonstrates the value of a systematic
approach to corresponding cohort comparisons, which is
particularly relevant for therapies evaluated exclusively or
predominantly in single-arm studies. A relevant question
in this respect is the appropriate range of C-cohorts to
include and the associated workload (almost 600 publica-
tions were assessed for the present analysis). The starting
point for the present comparative review was a reference
cohort with many diagnoses; therefore we included the
five largest evaluable diagnosis groups. In many other cir-
cumstances, it would be appropriate to analyse only one
diagnosis. In the present review, we restricted compari-
sons to C-cohorts with similar follow-up period and iden-
tical outcome measure. Depending on the research
question and the amount of available C-cohorts, further
restrictions could be applied e. g. regarding design, set-
ting, therapy and baseline status, as in the sensitivity anal-
yses of the present review. Notably, in our analyses these
restrictions, applied individually or simultaneously, had
only small effects on the results: the maximum effect was
an increase in the median effect size by 0.13 when the set-
ting of C-cohorts was restricted to primary care/health
maintenance organizations. Combined restrictions are
possible, but will further reduce the number of C-cohorts.
In this review, the combination of SA1 + SA2 + SA3 + SA4
Table 5: Baseline differences in standard deviations, stratified by diagnosis. Each comparison refers to one SF-36 scale at baseline: 
Mean score in AMOS cohort minus mean score in corresponding cohort, divided by standard deviation of score in AMOS cohort. A 
negative difference indicates that AMOS cohorts have worse health status than corresponding cohorts at baseline.
Diagnosis Median Interquartile range Ranges: Number (percentage) of comparisons N (total)
≤ -0.8 -0.79 to -0.5 -0.49 to -0.2 -0.19 to 0.19 0.2 to 0.49 0.5 to 0.79 ≥ 0.8
Asthma -0.02 -0.20 to +0.27 0 (0) 4 (5) 15 (20) 34 (44) 17 (22) 7 (9) 0 (0) 77 (100)
Depression -0.25 -0.51 to +0.03 10 (13) 9 (12) 28 (36) 19 (24) 9 (12) 0 (0) 3 (4) 78 (100)
Low back pain -0.05 -0.45 to +0.31 15 (7) 30 (15) 38 (19) 58 (29) 32 (16) 15 (7) 14 (7) 202 (100)
Migraine -0.42 -0.64 to -0.17 28 (19) 36 (24) 48 (32) 31 (21) 6 (4) 1 (1) 0 (0 150 (100)
Neck pain -0.37 -0.66 to -0.12 1 (10) 3 (30) 2 (20) 3 (30) 0 (0) 1 (10) 0 (0) 10 (100)
Total -0.22 -0.53 to +0.13 55 (11) 82 (16) 131 (25) 144 (28) 64 (12) 24 (5) 17 (3) 517 (100)
Table 6: Outcome comparisons in effect sizes, stratified by diagnosis. Each comparison refers to one SF-36 scale at the last evaluable 
follow-up of the corresponding cohort: Mean difference from baseline in AMOS cohort minus mean difference from baseline in 
corresponding cohort, divided by standard deviation of baseline score of AMOS cohort. A positive difference indicates that AMOS 
cohorts show larger improvements than corresponding cohorts.
Diagnosis Median Interquartile range Ranges: Number (percentage) of comparisons N (total)
≤ -0.8 -0.79 to -0.5 -0.49 to -0.2 -0.19 to 0.19 0.2 to 0.49 0.5 to 0.79 ≥ 0.8
Asthma 0.05 -0.18 to 0.30 1 (1) 4 (5) 13 (17) 33 (43) 18 (23) 6 (8) 2 (3) 77 (100)
Depression 0.17 -0.09 to 0.37 3 (4) 4 (5) 6 (8) 26 (33) 28 (36) 9 (12) 2 (3) 78 (100)
Low back pain 0.12 -0.12 to 0.33 9 (4) 10 (5) 22 (11) 77 (38) 57 (28) 21 (10) 6 (3) 202 (100)
Migraine 0.10 -0.08 to 0.35 0 (0) 2 (1) 16 (11) 77 (51) 34 (23) 14 (9) 7 (5) 150 (100)
Neck pain 0.44 0.23 to 0.54 0 (0) 0 (0) 1 (10) 1 (10) 5 (50) 3 (30) 0 (0) 10 (100)
Total 0.11 -0.11 to 0.35 13 (3) 20 (4) 58 (11) 214 (41) 142 (27) 53 (10) 17 (3) 517 (100)BMC Medical Research Methodology 2008, 8:11 http://www.biomedcentral.com/1471-2288/8/11
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Outcome comparisons stratified by diagnoses Figure 2
Outcome comparisons stratified by diagnoses. Differences between pre-post improvements of AMOS cohorts and 
improvements of corresponding cohorts for all SF-36 scales and summary measures, expressed in effect sizes and ordered in 
increasing magnitude: for all diagnoses and for individual diagnoses (altogether n = 517 comparisons). Positive effect sizes indi-
cate larger pre-post improvement in AMOS cohort than in corresponding cohort.
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Table 7: Outcome comparisons in effect sizes: Sensitivity analyses (SA)
Analysis Median Interquartile range Ranges: Number (percentage) of comparisons N (total) N
≤ -0.8 -0.79 to -0.5 -0.49 to -0.2 -0.19 to 0.19 0.2 to 0.49 0.5 to 0.79 ≥ 0.8 Comparisons Cohorts
Main analysis: any design, setting, 
intervention, and baseline status
0.11 -0.11 to 0.35 13 (3) 20 (4) 58 (11) 214 (41) 142 (27) 53 (10) 17 (3) 517 (100) 84
SA1: Design: only observational studies 
(excluding randomised controlled trials)
0.08 -0.14 to 0.28 6 (2) 11 (4) 40 (13) 140 (47) 77 (26) 21 (7) 6 (2) 301 (100) 44
SA2: Setting: only primary care/health 
maintenance organization
0.24 0.03 to 0.38 3 (2) 4 (3) 9 (7) 42 (30) 60 (43) 16 (12) 4 (3) 138 (100) 27
SA3: Intervention: only drugs, 
physiotherapy, other physical therapy, or 
mixed
0.08 -0.09 to 0.30 3 (1) 7 (2) 36 (11) 164 (50) 86 (26) 21 (6) 8 (2) 325 (100) 49
SA4: Baseline status: only comparisons 
with small baseline difference (< 0.50 
standard deviation)
0.08 -0.13 to 0.28 5 (1) 14 (4) 41 (12) 161(47) 81 (24) 29 (9) 9 (3) 340 (100) 81
SA1 + SA2 + SA3 + SA4 0.07 -0.03 to 0.19 0 (0) 0 (0) 2 (13) 10 (63) 3 (19) 0 (0) 1 (6) 16 (100) 5BMC Medical Research Methodology 2008, 8:11 http://www.biomedcentral.com/1471-2288/8/11
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resulted in only five evaluable C-cohorts with two diag-
noses.
A problem when defining narrow inclusion criteria for
any systematic review is that researchers familiar with the
pool of potentially eligible studies might choose inclusion
criteria that produce results favouring their research
agenda (inclusion criteria bias) [27]. This problem can be
prevented when broad criteria are used for the main anal-
ysis and restrictive criteria are applied secondarily, as in
the present review. A general advantage of applying both
broad and restricted inclusion criteria for one review is the
additional information on how results change when
inclusion criteria are altered.
Conversely, with some indications and outcome meas-
ures, the number of available C-cohorts may be very
small. In such cases it may be necessary to widen the
inclusion criteria, e. g. to include cohorts with other fol-
low-up periods and outcome measures than in the refer-
ence study. Another scenario is the situation of having a
body of C-cohorts from studies with very similar design,
interventions and control groups (e. g. placebo-controlled
randomised trials of one drug), which might enable
researchers to incorporate data also from control groups,
and to pool data and adjust for between-group differences
[28]. Corresponding cohort comparisons may also be
applied to safety aspects of medications and therapies,
and should take into account setting (e. g. spontaneous
reporting system, retrospective survey or prospective
cohort) and outcome measure (e. g. adverse events, sus-
pected adverse reactions or medically confirmed adverse
reactions) [29].
Conclusion
In this descriptive analysis, anthroposophic therapy was
associated with SF-36 improvements largely of the same
order of magnitude as improvements following other
treatments. Although these non-concurrent comparisons
cannot assess comparative effectiveness, they suggest that
improvements in health status following anthroposophic
therapy can be clinically meaningful. The analysis also
demonstrates the value of a systematic approach when
comparing a therapy cohort to corresponding therapy
cohorts.
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